2-羟基-5,6,7,8-四氢化萘-1-羧酸甲酯 | 59604-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 2-羟基-5,6,7,8-四氢化萘-1-羧酸甲酯
• 中文别名: 2-羟基-5,6,7,8-四氢萘-1-羧酸甲酯
• 英文名称: 2-hydroxy-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid methyl ester
• 英文别名: methyl 2-hydroxy-5,6,7,8-tetrahydronaphthalene-1-carboxylate；2-hydroxy-5,6,7,8-tetrahydro-[1]naphthoic acid methyl ester；2-Hydroxy-5,6,7,8-tetrahydro-[1]naphthoesaeure-methylester；methyl 2-hydroxy-5,6,7,8-tetrahydro-1-naphthoate
• CAS: 59604-96-5
• 化学式: C₁₂H₁₄O₃
• mdl: MFCD09258894
• 分子量: 206.241
• InChiKey: FGZPUQMMDVJQQN-UHFFFAOYSA-N

物化性质

• 熔点：
  40-43℃

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2918199090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H317,H319

反应信息

• 作为反应物：
  描述：

  2-羟基-5,6,7,8-四氢化萘-1-羧酸甲酯 在 镍 吡啶 、 盐酸 、 palladium diacetate 、 lithium hydroxide 、 氢气 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 吡啶 、 甲醇 、 二氯甲烷 为溶剂， -20.0~160.0 ℃ 、413.68 kPa 条件下， 反应 10.5h， 生成 2-{[(2-aminophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
  参考文献：
  名称：

  Discovery and Optimization of Anthranilic Acid Sulfonamides as Inhibitors of Methionine Aminopeptidase-2:  A Structural Basis for the Reduction of Albumin Binding

  摘要：

  Methionine aminopeptidase-2 (MetAP2) is a novel target for cancer therapy. As part of an effort to discover orally active reversible inhibitors of MetAP2, a series of anthranilic acid sulfonamides with micromolar affinities for human MetAP2 were identified using affinity selection by mass spectrometry (ASMS) screening. These micromolar hits were rapidly improved to nanomolar leads on the basis of insights from protein crystallography; however, the compounds displayed extensive binding to human serum albumin and had limited activity in cellular assays. Modifications based on structural information on the binding of lead compounds to both MetAP2 and domain III of albumin allowed the identification of compounds with significant improvements in both parameters, which showed good cellular activity in both proliferation and methionine processing assays.

  DOI：

  10.1021/jm0601001
• 作为产物：
  描述：

  2-羟基-1-萘酸甲酯 在 platinum(IV) oxide 氢气 、 溶剂黄146 作用下， 生成 2-羟基-5,6,7,8-四氢化萘-1-羧酸甲酯
  参考文献：
  名称：

  [EN] TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME
  [FR] COMPOSÉS DE TÉTRAZOLE ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION DE CEUX-CI

  摘要：

  本文介绍了四唑化合物及其在治疗医学疾病（如肥胖症）中的应用。提供了制备各种四唑化合物的制药组合物和方法。这些化合物被认为对甲硫氨酰基氨肽酶2具有活性。

  公开号：

  WO2012103333A1

文献信息

• Synthesis of Bicyclic Salicylates by [3+3] Cyclization of 1,3-Bis(Silyl Enol Ethers) with Cyclic 3-(Silyloxy)alk-2-en-1-ones
  作者：Nicole Höttecke、Helmut Reinke、Christine Fischer、Peter Langer

  DOI：10.1515/znb-2009-0616

  日期：2009.6.1

  Bicyclic salicylates were prepared by [3+3] cyclization of 1,3-bis(silyl enol ethers) with cyclic 3-(silyloxy)alk-2-en-1-ones. Graphical Abstract Synthesis of Bicyclic Salicylates by [3+3] Cyclization of 1,3-Bis(Silyl Enol Ethers) with Cyclic 3-(Silyloxy)alk-2-en-1-ones

  双环水杨酸酯是通过 1,3-双（甲硅烷基烯醇醚）与环状 3-（甲硅烷氧基）烷-2-烯-1-酮 [3+3] 环化制备的。通过 1,3-双（甲硅烷基烯醇醚）与环状 3-（甲硅烷氧基）烷-2-烯-1-酮的 [3+3] 环化合成双环水杨酸酯的图形摘要
• Aminotetralols
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04035512A1

  公开（公告）日：1977-07-12

  Novel aminotetralol compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, acyl derived from carboxylic acid, or a hydrocarbon group which may be substituted; --OZ.sup.1 is hydroxyl which may be protected; Y is hydrogen, acyl, hydroxyl which may be protected, amino which may be substituted, nitro, cyano or halogen; and n is zero, 1 or 2 with a proviso that when Y is hydrogen or hydroxyl which may be protected, n is not zero, and their salts, have excellent pharmacological activities such as strong bronchodilating activity. They are useful as medicines, for example, for treatment of asthma.

  新型氨基四氢萘化合物的化学式为##STR1##其中R.sup.1是氢、来自羧酸的酰基，或者可以被取代的烃基；--OZ.sup.1是可能被保护的羟基；Y是氢、酰基、可能被保护的羟基、可能被取代的氨基、硝基、氰基或卤素；n为零、1或2，但当Y为氢或可能被保护的羟基时，n不为零。这些化合物及其盐具有出色的药理活性，如强效的支气管扩张活性。它们可用作药物，例如用于治疗哮喘。
• [EN] TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME<br/>[FR] COMPOSÉS DE TÉTRAZOLE ET PROCÉDÉS DE PRÉPARATION ET D'UTILISATION DE CEUX-CI
  申请人：ZAFGEN CORP

  公开号：WO2012103333A1

  公开（公告）日：2012-08-02

  Described herein are tetrazole compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tetrazole compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本文介绍了四唑化合物及其在治疗医学疾病（如肥胖症）中的应用。提供了制备各种四唑化合物的制药组合物和方法。这些化合物被认为对甲硫氨酰基氨肽酶2具有活性。
• [EN] NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS<br/>[FR] NAPHTALENE-CARBOXAMIDES UTILISES EN TANT QU'ANTAGONISTES DES RECEPTEURS DES TACHYKININES
  申请人：ZENECA LTD

  公开号：WO2000020389A1

  公开（公告）日：2000-04-13

  A compound having formula (I) wherein R1 is oxo, -ORa, -OC(=O)Rb; or (A); R2 is H; or R?1 is -ORc and R2 is -ORd; or R1 and R2¿ together form -O(CH¿2?)mO-; and any pharmaceutically-acceptable salt thereof along with their use in treating depression, anxiety, asthma, rheumatoid arthritis, Alzheimer's disease, cancer, schizophrenia, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, anxiety, emesis, Huntington's disease, psychoses including depression, hypertension, migraine, bladder hypermotility, or urticaria, along with methods of making the compounds and pharmaceutical compositions containing the compounds.

  化合物式(I)的化合物，其中R1是氧代、-ORa、-OC（=O）Rb；或（A）；R2是H；或者R1是-ORc且R2是-ORd；或者R1和R2在一起形成-O（CH2）mO-；以及其任何药学上可接受的盐，用于治疗抑郁症、焦虑症、哮喘、类风湿性关节炎、阿尔茨海默病、癌症、精神分裂症、水肿、过敏性鼻炎、炎症、疼痛、胃肠过度运动、焦虑症、呕吐、亨廷顿病、包括抑郁症、高血压、偏头痛、膀胱过度运动或荨麻疹的方法，以及制备这些化合物和含有这些化合物的制药组合物。
• TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME
  申请人：Dyke Hazel Joan

  公开号：US20130331420A1

  公开（公告）日：2013-12-12

  Described herein are tetrazole compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tetrazole compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本文描述了四唑化合物及其在治疗医学疾病（如肥胖症）方面的应用。提供了制备各种四唑化合物的制药组合物和方法。这些化合物被认为具有对甲硫氨酰基氨肽酶2的活性。